You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Avamys Product Overview

Avamys (fluticasone furoate) is indicated for the treatment of symptoms of allergic rhinitis in adults, adolescents and children (aged two and over). 1

Request a device


*Vs fluticasone propionate, budesonide, mometasone furoate and ciclesonide.
**Multicentre, randomised, double-blind, crossover study (n=300) where patient preferences were determined by using three questionnaires (Overall Preference, Immediate Attributes and Delayed Attributes).

AR: allergic rhinitis; FFNS: fluticasone furoate nasal spray; INCS: intranasal corticosteroids; MFNS: mometasone furoate nasal spray


  1. Fluticasone Furoate Global Data Sheet; version 11, 03 April 2018.
  2. Canonica GW, Mullol J, Pradalier A, Didier A. Patient perceptions of allergic rhinitis and quality of life: findings from a survey conducted in Europe and the United States. World Allergy Organ J 2008;1(9):138–144.
  3. Seidman M, Gurgel RK, Lin SY, et al. Clinical Practice Guideline: Allergic Rhinitis.Otolaryngol Head Neck Surg 2015;152(18):S1–S43.
  4. Linneberg A, Dam Petersen K, Hahn-Pedersen J, et al. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy 2016;14:12.
  5. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl. 86):8–160.
  6. Vasar M, Houle PA, Douglass JA, et al. Fluticasone furoate nasal spray: Effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008;29(3);313–321.
  7. Baumann D, Bachert C, Högger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39(10):1540–1550.
  8. Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8(1):54.
  9. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660–667.
  10. Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol 2016;7(4):e183–e192.
  11. Brozek J, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
  12. Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2017;47:856–889.
  13. Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance from the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017;167(12):876–881.
  14. Santos A, Borrego LM, Rotiroti G, et al. The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice. Clin Transl Allergy. 2015;5:2.

Avamys is a registered trademark of the GlaxoSmithKline group of companies